E-0474(E-0474) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

心血管疾病

在研适应症-

非在研适应症

心律失常

原研机构

EBEWE Pharma Ges.m.b.H. Nfg.KG

在研机构-

非在研机构

EBEWE Pharma Ges.m.b.H. Nfg.KG

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 E-0474 相关的临床结果

登录后查看更多信息

100 项与 E-0474 相关的转化医学

登录后查看更多信息

100 项与 E-0474 相关的专利（医药）

登录后查看更多信息

1

项与 E-0474 相关的文献（医药）

1996-05-29·International Journal of Cancer1区 · 医学

Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a K^drestricted immunogenic peptide

1区 · 医学

Article

作者: Lichlyter, Darcy ; Jones, Richard F. ; Gill, Randall F. ; Abastado, Jean‐Pierre ; Wei, Wei‐Zen

A synthetic peptide E474 SFAVATTAL, derived from the sequence of mouse mammary tumor virus envelope protein, was previously shown to bind class I MHC Kd. Immunization of BALB/c mice with E474 in 50% incomplete Freund's adjuvant (IFA) followed by in vitro stimulation of immune cells with E474-coated antigen-presenting cells resulted in peptide-specific cytotoxic T lymphocytes (CTL). Furthermore, anti-E474 CTL lysed mammary tumor cell lines D2F2 and D2A1, derived from a spontaneous tumor that arose in BALB/c pre-neoplastic hyperplastic alveolar nodule (HAN) D2 line. Expression of Kd by D2A1 and D2F2 cells was verified by flow cytometry, and lysis of D2 tumor cells was blocked by monoclonal antibody 31-34-S, which interacted with the peptide-binding region of Kd, supporting the recognition of E474 in Kd by anti-E474 CTL. Immunization of BALB/c mice with E474 before D2F2 tumor challenge resulted in reduced tumor growth. Therefore, E474 is naturally processed and presented by these tumor cells and can induce anti-tumor immunity.

100 项与 E-0474 相关的药物交易

登录后查看更多信息